Lipella Pharmaceuticals Faces Delisting Concerns
Ticker: LIPO · Form: 8-K · Filed: Apr 19, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Lipella Pharmaceuticals might be delisted, check their listing status ASAP!
AI Summary
Lipella Pharmaceuticals Inc. filed an 8-K on April 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was on April 17, 2024. The company is incorporated in Delaware and its principal executive office is located in Pittsburgh, PA.
Why It Matters
This filing indicates potential issues with Lipella Pharmaceuticals' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- April 19, 2024 (date) — Filing Date
- April 17, 2024 (date) — Earliest Event Date
- Delaware (jurisdiction) — State of Incorporation
- Pittsburgh, PA (location) — Principal Executive Office
FAQ
What specific listing rule or standard has Lipella Pharmaceuticals Inc. failed to satisfy?
The filing does not specify the exact listing rule or standard that Lipella Pharmaceuticals Inc. has failed to satisfy, only that a notice has been issued.
What is the earliest date of the event reported in this 8-K filing?
The earliest date of the event reported in this 8-K filing is April 17, 2024.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Where is Lipella Pharmaceuticals Inc.'s principal executive office located?
Lipella Pharmaceuticals Inc.'s principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What type of SEC filing is this and what is its primary purpose?
This is a Form 8-K, a current report filed to announce major corporate events, and its primary purpose here is to provide notice of delisting or failure to satisfy a continued listing rule.
Filing Stats: 1,138 words · 5 min read · ~4 pages · Grade level 15.1 · Accepted 2024-04-19 16:15:24
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Capital M
- $1.00 — ment to maintain a minimum bid price of $1.00 per share of its Common Stock, as set f
Filing Documents
- g084189_8k.htm (8-K) — 40KB
- 0001753926-24-000805.txt ( ) — 213KB
- lipo-20240419.xsd (EX-101.SCH) — 3KB
- lipo-20240419_lab.xml (EX-101.LAB) — 33KB
- lipo-20240419_pre.xml (EX-101.PRE) — 22KB
- g084189_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 19, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer